Resistance to antiretrovirals appears to be waning in certain treatment-naive and treatment-experienced populations in high-income countries, according to large new analyses presented at the International HIV and Hepatitis Virus Drug Resistance Workshop [1, 2] . In low-income countries, where HIV prevalence is highest and antiretroviral therapy is expanding, researchers are working hard to begin characterizing HIV resistance patterns. At the Resistance Workshop, recently completed work showed that absence of routine viral load monitoring in resource-poor settings poses an acute risk of undetected virological failure, accumulation of resistance mutations and resulting compromised second-line therapy [3] (see Epidemiology of HIV resistance section). Other research from sub-Saharan Africa documented low-frequency resistance mutations in untreated South Africans [4] (see Application of new sequencing techniques), increasing frequency of transmitted resistance mutations in Rwanda [5] , a resistance transmission prevalence as high as 11.5% in rural Cameroon [6] , and high rates of resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) in children treated in the Central African Republic [7] .
In high-income countries, reported declines in antiretroviral resistance rates can be attributed to routine viral load monitoring and genotyping before treatment begins and during therapy. In recent years, development of more potent and more tolerable antiretroviral combinations, some of them with higher barriers to resistance, contributes to better viral control and thus to potentially diminished evolution of resistance mutations [1, 2] . As a result, more research can now focus on new issues such as the effect of resistance on preexposure prophylaxis strategies, the promise and limitations of new sequencing technologies and the mechanisms of HIV drug resistance.
For the first time this Workshop devoted a substantial proportion of time to resistance to antivirals for HBV and HCV infection. Resistance research in the hepatitis Introduction arena must focus primarily on the array of new agents being developed to treat these infections. Although several NRTIs are licensed to treat HBV infection, until now only interferon (IFN) and ribavirin (RBV) have been available to control HCV. That picture is evolving rapidly however, as drug developers are testing numerous anti-HCV candidates in different classes. Understanding resistance to these new agents will be vital to their effective use, as hepatitis virus resistance researchers strive to learn from mistakes made in the early use of antiretrovirals.
Epidemiology of HIV resistance
Resistance mutations accumulate with ongoing failing therapy A fundamental principle of HIV dynamics is that the viral genome mutates prolifically when the virus is allowed to replicate. When HIV is allowed to replicate in the presence of incompletely suppressive therapy, the mutations that evolve will confer resistance to the antiretrovirals being taken and to other drugs that share a similar resistance profile. For these reasons, antiretroviral guidelines in high-income countries call for regular viral load monitoring to detect virological failure early [8] . These guidelines also recommend genotyping upon suboptimal virological response or virological failure to determine whether resistance-conferring mutations have evolved and which antiretrovirals may be affected by those mutations.
The WHO also advises that 'periodic monitoring (of HIV-1 viral load) is essential' [9] . However, many clinics in resource-constrained regions do not regularly assess viral load in antiretroviral-treated patients because of budgetary, logistical and technical constraints. Viral sequencing to detect resistance mutations is even rarer in such clinics.
To assess the evolution of resistance mutations when patients continue the same antiretroviral combination after virological rebound, researchers in the Netherlands and South Africa performed twice-yearly viral load testing in 735 adults and 101 children starting their first antiretroviral regimen, which included an NNRTI [3] . Study participants were treated at the Ndlovu Medical Care Centre in rural Limpopo, South Africa.
In patients who first reached a viral load <50 HIV-1 RNA copies/ml then rebounded above 1,000 copies/ml, Barth et al. [3] recorded standard genotypic test results at three points: before treatment began, when virological failure was first detected (time 1) and 6 or 12 months later (time 2). The investigators also determined how many of these individuals met WHO criteria for treatment failure because of an insufficient CD4 + T-cell gain or HIV-1 RNA>10,000 copies/ml.
Of the 836 individuals who began therapy, 642 (77%) reached a plasma viraemia <50 HIV-1 RNA copies/ml. Of those 642 responders, 145 (23%) had a rebound >1,000 HIV-1 RNA copies/ml. Despite virological failure by this definition, 58 patients (40%) continued the same antiretrovirals.
The researchers had complete genotypic resistance data on 26 of the 58 patients who continued the same regimen with HIV-1 RNA>1,000 copies/ml, all of whom were infected with subtype C HIV-1. In these individuals the total number of mutations rose from 72 at time 1 to 98 at time 2 (a 36% increase), and the average number of mutations per person rose from 2.8 to 3.8. The investigators counted 47 NNRTI mutations and 25 NRTI mutations at time 1. As treatment continued with the same failing regimen, the number of NRTI mutations rose to 44 (increase of 76%) and the number of NNRTI mutations to 54 (increase of 15%). The number of thymidine analogue mutations rose from 4 to 14 over this period and the number of K65R mutations increased from 3 to 6.
Using the Stanford genotypic sensitivity score to calculate the number of drugs active against each patient's resistant virus, the researchers found that the number of active NNRTIs fell from 1.0 to 0.7 from time 1 to time 2, while the number of active NRTIs declined from 5.1 to 4.0.
Although these patients would be classified as virological failures in any Western country, at time 2 only 43% met WHO criteria for CD4 + T-cell failure and only 62% met criteria for virological failure (HIV-1 RNA>10,000 copies/ml). The investigators argued that their results underline the urgent need for wider access to viral load monitoring in low-income countries.
Accumulation of resistance mutations has also been reported in populations from high-income countries when an incompletely suppressive regimen continues. For example, EuroSIDA cohort investigators reported an average 6-monthly increase of 1.96 resistance mutations in 110 patients with a detectable viral load [10] . Over the same period, those patients lost an average 1.25 mutations.
Downturn in transmitted resistance in the United States
Rates of transmitted drug resistance (TDR) appeared to peak in the United States around 2005 and to decline in more recent years, according to a study of 3,829 antiretroviral-naive individuals seeking enrolment or enrolling in clinical trials in 36 states and Washington, DC [1] . Although patients entering clinical trials do not comprise a nationally representative sample, the results offer one perspective on TDR in a large US population. An additional caveat is that recent declines in TDR reached statistical significance only for NNRTI-related mutations in this study. [1] counted major mutations that confer resistance to NRTIs, NNRTIs or protease inhibitors (PIs). Using the 2009 International AIDS Society (IAS)-USA list of mutations [11] and the WHO TDR surveillance list [12] , the investigators charted an overall TDR prevalence of 12% by IAS-USA and 13% by WHO. According to the IAS-USA list, TDR prevalence rose from 5% in 2000 
K65R mutation detected in acute infection samples from 1997 to 1999
K65R, a resistance mutation usually associated with tenofovir disoproxil fumarate but which stavudine can select in vitro, could be detected by sensitive real-time PCR in 2 of 13 US patients during acute HIV infection before the year 2000 [13] . Three of these 13 patients (23%) were infected with K65R or K70R, a thymidine NRTI mutation.
Lipscomb et al. [13] from CDC used real-time PCR to search for K65R, M41L and K70R in longitudinally collected seroconversion samples from 13 individuals infected with HIV-1 subtype B. M41L and K70R were prevalent in the years when these individuals were infected (1997-1999) but K65R was not. The assays used had viral population detection limits of 0.3% for K65R, 0.8% for M41L and 2.0% for K70R.
Three patients had real-time PCR evidence of at least one of these drug resistance mutations during acute infection. K70R could be detected at a frequency never exceeding 50% 14 and 12 days before seroconversion in one patient infected in 1998. Viral rebound samples at seroconversion had no detectable K70R. One patient infected in 1999 had K65R 9 days after seroconversion at the limit of detection (0.3%). In this patient, resistance mutations associated with thymidine NRTIs (zidovudine and stavudine) and with didanosine could be detected at a frequency of 1.6% in a separate clone. In a third patient infected in 1997, real-time PCR identified K65R and K70R during HIV-1 RNA escalation. In this patient, five distinct thymidine NRTI and didanosinerelated mutations made up 41.8% of the clones and were not linked to K65R.
In both patients with K65R, the K65R subpopulation was linked to the R83K polymorphism, which is a mutation that may be enriched by stavudine. That finding, together with the pattern of thymidine analogue mutations in the other variants, suggested that stavudine had originally selected these K65R mutations. In both patients K65R was present only at minority levels and decayed within 2 months of detection.
Lipscomb et al. [13] proposed that detection of K65R at low levels suggests these variants were minor constituents of the infecting viral swarm. Coexistence of K65R with other mutations, the investigators suggested, indicates that multiple, distinct minority NRTI resistant variants can be transmitted during primary infection.
Resistance transmission and viral clustering in a large Italian cohort
HIV-1 sequencing in a large Italian cohort determined that 40% of transmissions from antiretroviralexperienced patients with a known seroconversion date involved virus bearing resistance mutations [14] . Phylogenetic analysis showed that nearly one quarter of sequences from antiretroviral-naive people clustered into genetically related transmission groups.
Prosperi et al. [14] used a novel automated method to detect clustered virus in large phylogenetic trees instead of relying on visual inspection of trees or distance-based analysis. The investigators extracted HIV-1 subtype B sequences of antiretroviral-naive and antiretroviral-experienced individuals from the Italian ARCA database. They defined resistance as presence of at least one IAS-USA 2009 mutation, counting only major mutations among those conferring resistance to PIs [11] .
Of the 11,541 sequences analysed, 9% were from antiretroviral-naive individuals, 60% from antiretroviral-experienced patients and 31% from individuals with only a partial antiretroviral history. Median sequencing year was 2004 (interquartile range 2002 to 2007). Among treatment-naive people, 119 (12%) had any resistance mutation, while among treatment-experienced patients, 5,224 (75%) had any resistance mutation.
Sequences from 23% of antiretroviral-naive individuals fell into transmission clusters and 6 of 298 transmission clusters (2%) consisted entirely of antiretroviral-naive individuals. Among sequences from antiretroviral-experienced patients, 18.3% could be linked to transmission clusters. Only 3% of cohort members had a known HIV-1 seroconversion date at the time of this analysis. Among 312 antiretroviral-experienced patients with known seroconversion dates, the investigators found evidence of transmission in 10 treated individuals (3.2%). Of these 10 individuals, 4 (40%) had at least one resistance mutation. Prosperi et al. [14] + T-cell count were not associated with clustering in this analysis.
Prosperi et al. [14] cautioned that their analysis is limited by lack of complete and cleaned data for many cohort members. For example, HIV-1 transmission category could not be established for 41% of patients, 40% could not be classified as Italian or non-Italian, 31% had only a partial or unknown treatment history, and 97% had an unknown HIV-1 seroconversion date. The ARCA consortium is currently working to collect demographic information on all cohort members to refine these results.
M184V/I virus is less fit in antiretroviral-naive individuals
Antiretroviral-naive patients infected with virus bearing the M184V/I mutations had lower plasma viraemia than untreated patients infected with virus harbouring other resistance mutations or individuals infected with wild-type virus [15] . This large study in the United Kingdom offers the first in vivo evidence that M184V/I replicates significantly more poorly than wild-type virus in the absence of drug pressure, but that finding may have little clinical or public health relevance.
When created by site-directed mutagenesis, HIV-1 bearing resistance mutations has a lower replication capacity ('fitness') than wild-type virus. As a result, people infected with mutation-bearing virus would be expected to have lower initial plasma viraemia than people infected with more fit wild-type virus. However, that hypothesis remained unproved until this study of 7,994 UK individuals whose virus was genotyped before they began antiretroviral therapy and who had HIV-1 RNA and CD4 + T-cell measurements within 6 months of genotyping and before therapy. Harrison et al. [15] defined transmitted drug resistance according to the 2007 WHO surveillance list [16] .
Among the 7,994 individuals analysed, 12% got genotyped in 1997-1999, 36% in 2000-2004 and 52% in 2005-2007 . Most cohort members (62%) were men who have sex with men, while 16% were heterosexual women and 10% heterosexual men. HIV-1 subtype B predominated (68%), followed by subtypes C (13%), A (4%), CRF_AG (4%) and others (11%). CD4 + T-cell counts averaged 361 cells/mm 3 and plasma viraemia 40,000 copies/ml.
The study group included 709 individuals (9%) infected with HIV-1 harbouring one or more resistance mutations, including 61 individuals (0.8%) with M184V/I, 53 of whom also had other mutations. Those with M184V/I had an HIV-1 RNA level 0.33 log 10 copies/ml (53%) lower than individuals infected with wildtype virus (P=0.002). No other mutation affected the level of plasma viraemia.
Harrison et al. [15] stressed that the individuals analysed had chronic HIV-1 infection when tested, not acute infection. Thus, other people in this study group may have been infected with mutant virus that reverted to wild-type before genotyping. As a result, the analysis does not address the initial effect of transmitted resistance mutations on plasma viraemia. The investigators also suggested their findings indicate that any population-level effect of transmitted mutations on transmission risk or clinical disease progression is likely to be small because only M184V/I had such an effect on plasma viraemia level and overall M184V/I prevalence in this large group was <1%.
HIV pathogenesis, fitness and resistance

Resistance emergence during low-level viraemia
New resistance mutations emerged in 43% of participants in two trials during treatment with an incompletely suppressive regimen [17] . The most frequent mutations to emerge during 'near-target viral suppression' were M184V/I (conferring resistance to lamivudine and emtricitabine) and K103N/R (conferring resistance to efavirenz and nevirapine).
Taiwo et al. [17] retrospectively analysed viral isolates from 1,234 previously untreated people who enrolled in two randomized AIDS Clinical Trials Group (ACTG) studies, ACTG A5095 and ACTG A5142, which involved treatment with three-or four-drug combinations including efavirenz, lopinavir/ritonavir and abacavir. The investigators defined near-target viral suppression as plasma viraemia between 50 and 1,000 copies/ml at least twice during a 6-month period or longer while on randomized therapy. Incomplete suppressors with three or more HIV-1 RNA results could have one level <50 copies/ml or one >1,000 copies/ml.
Of the 1,234 trial participants analysed, 65 (5%) had near-target viral suppression. Median pretreatment HIV-1 RNA in these patients stood at 5.1 log 10 copies/ml and median CD4 + T-cell count at 121 cells/ mm 3 . Median first week of near-target viral suppression was trial week 39 (10th-90th percentile 30 to 97) and median duration of incomplete suppression was 38 weeks (10th-90th percentile 24 to 48).
Taiwo et al. [17] had pretreatment samples from 59 of 65 patients with incomplete suppression, from 59 patients during near-target viral suppression and from 54 patients during both periods. Standard sequencing detected pretreatment resistance mutations in 13 of 59 samples (22%), always either an NNRTI-related mutation of a reverse transcriptase (RT) codon 69 insertion. During near-target viral suppression, 23 of 54 samples (43%) harboured a new resistance mutation, including M184V/I in 14 isolates and K103N/R in 11. No PI-related mutations were detected before treatment or during near-target viral suppression.
Several variables favoured emergence of new mutations during near-target viral suppression, including black race (Table 1) , higher minimum plasma viraemia during incomplete suppression (62 HIV-1 RNA copies/ ml with new resistance versus <50 copies/ml without resistance; P=0.003), maximum plasma viraemia during incomplete suppression (368 copies/ml with new resistance versus 143 copies/ml without new resistance; P=0.008) and estimated average HIV-1 RNA value during the observation period (137 copies/ml with new resistance versus 69 copies/ml without new resistance; P<0.001). Taiwo et al. [17] stressed that, although higher plasma viraemia favoured emergence of new mutations, some mutations appeared at very low HIV-1 RNA levels.
After the presentation, Taiwo and Workshop attendees discussed reasons for the correlation between black race and emergence of new mutations during near-target viral suppression. Two possible factors are worse antiretroviral adherence by black study participants [18] and race-based genetic factors affecting efavirenz metabolism and plasma concentrations [19] . Taiwo et al. [17] did not analyse antiretroviral concentrations for this study.
Protection against resistant rectal SHIV with Truvada™
Intermittently administered fixed-dose tenofovir disoproxil fumarate/emtricitabine (Truvada™) protected five of five macaques from rectal exposure to an emtricitabine-resistant simian HIV (SHIV) in a randomized trial [20] . Although the study design did not precisely reflect conditions in ongoing pre-exposure prophylaxis (PrEP) trials of daily tenofovir disoproxil fumarate/emtricitabine, the results suggest that an intermittent nucleotide/nucleoside regimen can lower the risk of HIV acquisition in humans, even when the infecting virus bears a mutation conferring resistance to emtricitabine.
García-Lerma et al. [21] reported earlier that intermittent tenofovir disoproxil fumarate/emtricitabine can protect macaques from rectal exposure to wildtype SHIV [21] , a simian immunodeficiency virus with an HIV envelope. The new study involved 10 macaques exposed to a SHIV isolate engineered by site-directed mutagenesis to carry the M184V mutation, which confers resistance to emtricitabine and lamivudine. The mutant SHIV was more than 100-fold resistant to emtricitabine and threefold more susceptible to tenofovir disoproxil fumarate than wildtype virus. Replication capacity of M184V-bearing SHIV was 30-fold lower than the replication capacity of non-mutant SHIV.
In total, five macaques received human-equivalent doses of tenofovir disoproxil fumarate/emtricitabine by gavage 3 days before and 2 h after 14 weekly exposures to M184V-bearing SHIV at a dose of 40 median tissue culture infective doses. A total of five macaques remained untreated and were used as controls. Five of five treated macaques were protected from M184V SHIV infection after all 14 exposures. All five untreated macaques became infected after a median of three exposures (range 2 to 11 exposures; P=0.0008). Peak plasma viraemia in untreated animals averaged 6.1 log 10 copies/ml, significantly lower than peak loads in earlier research involving 22 macaques rectally exposed to wild-type SHIV.
García-Lerma et al. [21] suggested that several factors may contribute to protection of treated macaques from emtricitabine-resistant SHIV in this study: hypersusceptibility of M184V SHIV to tenofovir disoproxil fumarate, residual activity of emtricitabine against M184V SHIV, high emtricitabine and tenofovir disoproxil fumarate concentrations in rectal tissues, and the lower replication capacity of M184V SHIV than wildtype SHIV reflected in the blunted plasma viraemia of infected animals. After the presentation of these results, Workshop attendees noted that trial conditions do not mirror those in tenofovir disoproxil fumarate/emtricitabine PrEP trials because the macaques also received a postexposure prophylaxis dose of the two antiretrovirals. García-Lerma acknowledged this fact but also clarified that current trials with daily PrEP in effect include both a pre-and a post-exposure drug dose. The investigators created M184V mutants by making two nucleotide changes (ATG to GTT) to ensure that mutant SHIV would not revert to wild-type during early infection events and compromise the PrEP efficacy monkey trial. Attendees observed that a single nucleotide change usually yields M184V mutant virus in humans and that this mutant may rapidly revert to wild-type after transmission.
Factors affecting emergence of intersubtype HIV-1 recombinants
Recombination of HIV-1 circulating in human populations drives viral genetic diversity and could have pathophysiological consequences affecting vaccine development as well as other clinical ramifications.
To assess factors affecting intra-and intersubtype recombination of HIV-1 subtypes, Galli et al. [22] designed experiments to assess three such factors: efficiency of HIV-1 RNA copackaging, recombination rates and replication fitness of recombinants [22] . They devised a single-virion analysis method to assess RNA copackaging by direct examination of RNA content in individual viral particles using fluorescence microscopy. The investigators used single-genome sequencing to analyse viruses after a single round of replication without the requirement for pol gene function and after multiple rounds of replication when pol function is required.
Single-virion analysis showed that HIV-1 RNAs from different proviruses can be copackaged. Copackaging is inefficient, however, with RNAs containing GCGCGC or GTGCAC in their dimerization initiation signal, a trait of subtype B and C viruses, respectively. Galli et al. [22] concluded that the identity of the dimerization initiation signal can change the frequency of heterozygous viruses and that HIV-1 variants with different dimerization initiation signal sequences form heterozygous viruses less efficiently than variants with the same dimerization initiation signal.
The single-genome sequencing experiments showed that the rate of intersubtype B and F recombination is slightly lower than the rate of intrasubtype recombination. After a single round of replication, without pol gene function required, crossover junctions in both intrasubtype and intersubtype recombinants were distributed throughout the pol gene. In contrast, after multiple rounds of replication, with the requirement for pol gene function, crossover junctions were distributed through the pol gene for intrasubtype recombinants. However, under these conditions, crossover junctions clustered near the 3′-end of the pol gene for intersubtype recombinants.
Further experiments involving multiple rounds of replication of subtype B and F viruses determined that many newly generated intersubtype recombinants are eliminated during viral replication. Galli et al. [22] proposed that intersubtype recombination often disrupts distant coadapted sequences in the viral genomes, a process resulting in lower replication fitness of recombinants.
The investigators suggested that, taken together, their findings point to at least three barriers to emergence of intersubtype recombinants: inefficient copackaging of RNAs from different subtypes, a lower intersubtype recombination rate than intrasubtype recombination rate and quick elimination of newly generated intersubtype recombinants.
So far, single-genome sequencing results reflect experiments involving only B and F subtypes. The investigators plan to pursue their recombination research with other subtypes.
Only one HIV-1 DNA molecule in most lymph node CD4 + T-cells
Most lymph node CD4 + T-cells analysed in five patients chronically infected with HIV-1 contained a single HIV-1 DNA molecule and most CD4 + T-cells in peripheral blood also contained a single HIV-1 DNA copy [23] . This study by Josefsson et al. [23] found that viral DNA in lymph node T-cells was phylogenetically indistinguishable from DNA in peripheral blood T-cells.
HIV-1 levels in lymph nodes are assumed to be higher than in peripheral blood in chronically infected individuals, but relationships between the viruses in these two compartments remains incompletely understood. Assessing HIV-1 DNA concentrations in lymph nodes can help define the potential for recombination between viral species in an individual. Only when a cell is sequentially or simultaneously infected with two HIV-1 virions can recombination occur. To characterize HIV-1 DNA levels and genetic relationships in lymph node and peripheral blood CD4 + T-cells, Josefsson et al. [23] developed a single-cell sequencing technique to examine viral DNA molecules in single cells from the peripheral blood and lymph nodes.
The five study participants had plasma viraemia ranging from 3,618 to 32,000 HIV-1 RNA copies/ ml and CD4 + T-cell counts ranging from 121 to 935 cells/mm 3 . In naive (CD4RO-/CD27+) and memory (CD4RO+/CD27-) CD4
+ T-cells in peripheral blood, a large majority of samples had a single HIV-1 DNA molecule rather than double or triple molecules ( Table  2 ). The same distribution held true for both naive and memory CD4
+ T-cells in lymphoid tissue. Josefsson et al. [23] found no correlation between frequency of infection and viral RNA in cells from peripheral blood or lymph node tissue. CD4 + T-cell count did correlate positively with infection frequency in naive T-cells from lymphoid tissue. Phylogenetic analysis revealed little genetic difference between viral populations in CD4 + T-cells in peripheral blood, CD4
+ T-cells in lymphoid tissue and extracellular HIV in plasma. Josefsson et al. [23] proposed that this genetic similarity implies lack of compartmentalization of these viral populations in chronically infected individuals.
Workshop attendees noted that the low potential for viral recombination suggested by the predominance of single DNA molecules in infected cells is at odds with research indicating high intrapatient HIV-1 recombination rates. Palmer suggested that the minority of cells infected with multiple viruses may account for calculated intrapatient recombination rates [24] .
Most lymph node genes are negatively associated with HIV-1 replication
Almost 95% of genes analysed in lymph node samples from HIV-1-infected people were negatively associated with viral replication [25] . Paradoxically, the minority of genes positively associated with HIV-1 replication are usually considered to be involved in innate and adaptive immune defences.
Smith et al. [25] used a microarray approach to identify gene expression in inguinal lymph nodes collected from 22 antiretroviral-naive patients at various stages of HIV-1 infection and with a range of HIV-1 RNA levels in plasma. The investigators used a linear regression model to explore relationships between gene expression and plasma viraemia in these patients.
Of 592 transcripts related to HIV-1 replication, 558 (94%) correlated negatively with replication, while the remaining 6% correlated positively. Approximately half of the negatively associated genes regulate immune activation, while most of the others regulate cellular metabolism or tissue repair. Smith et al. [25] highlighted four clusters of negatively associated genes: gene products that inhibit cell activation or proliferation, gene products that modify histones, gene products involved in collagen synthesis and potential restriction factors.
Nearly three quarters of the genes positively associated with viral replication regulate immune defences, while others control cell trafficking, immune activation, cellular metabolism, tissue repair and apoptosis. Many of these positively correlated genes reflect functions of the heightened IFN response associated with higher plasma viraemia.
Smith et al. [25] proposed that the predominance of negative correlations between gene expression and plasma viraemia underlines the importance of genes that regulate target cell activation and genes that code for potential host restriction factors as important determinants of HIV-1 RNA level.
Attendees suggested two limitations of this study. First, an analysis identifying correlations between gene expression and an outcome such as plasma viraemia do not necessarily imply cause and effect. Second, although the inguinal lymph node is relatively easy to biopsy, it is bombarded by antigen. Thus, analysis of control lymph nodes from HIV-1-negative volunteers could be enlightening.
Resistance to new antiretrovirals
Temporal order of resistance to raltegravir, efavirenz and NRTIs
Raltegravir-related resistance mutations were slower to emerge than mutations conferring resistance to efavirenz, lamivudine or emtricitabine in a study of patients enrolled in two clinical trials [26] . Efavirenzrelated mutations usually emerged at the same time as lamivudine/emtricitabine mutations. The analysis involved previously untreated patients enrolled in the Phase II protocol 004 trial [27] or the Phase III STARTMRK trial [28] . Both trials compared the integrase inhibitor raltegravir with the NNRTI efavirenz in patients also taking tenofovir disoproxil fumarate with either lamivudine or emtricitabine. Raltegravir and efavirenz proved virologically equivalent in the two studies.
Among 441 patients randomized to raltegravir in these trials, 10 (2%) had virological failure with detectable resistance mutations, as did 11 of 320 patients (3%) randomized to efavirenz. Resistance to tenofovir disoproxil fumarate was rare in both trials.
Of the 11 patients in whom efavirenz failed, mutations conferring resistance to efavirenz emerged in five of them at the same time as mutations conferring resistance to lamivudine or emtricitabine. All of the other six patients had detectable efavirenz mutations on failure, but four of these six had no lamivudine/emtricitabine mutations. In total, three of these four individuals had no detectable lamivudine/emtricitabine mutations through 13, 20 and 30 weeks of follow-up, while the fourth person stopped the regimen after emergence of the K103N efavirenz mutation.
Of the 10 patients whose raltegravir regimen failed, lamivudine/emtricitabine mutations developed in eight individuals before raltegravir-related mutations could be detected. Raltegravir mutations emerged from 4 weeks to more than 1 year after mutations conferring resistance to lamivudine/emtricitabine. In two patients, raltegravirrelated mutations appeared at the same time or within 1 week of lamivudine/emtricitabine mutations. In this 10-patient group, raltegravir mutations never emerged before lamivudine/emtricitabine mutations.
These results suggest that raltegravir has a higher barrier to resistance than efavirenz in previously untreated patients. The findings also underscore the importance of switching from failing antiretrovirals before mutations evolve to confer resistance to other drugs in the regimen. Workshop attendees observed that several patients in this analysis continued all drugs in a failing regimen much longer than most clinicians would consider appropriate.
The SWITCHMRK trials yielded evidence that raltegravir is more vulnerable to resistance than continued lopinavir/ritonavir in virologically suppressed patients, if those patients have a history of NRTI failure [29] . Results of a 222-patient randomized trial presented at the Resistance Workshop indicated that switching from a PI to raltegravir did not appear to compromise continued viral suppression if patients did not have a record of NRTI resistance mutations [30] .
Inhibition of resistant integrase with S/GSK1349572
S/GSK1349572 (or 572 for short), an experimental strand-transfer integrase inhibitor, inhibited wildtype integrase as well as raltegravir did in an in vitro system [31] . Compared with raltegravir, 572 had stronger and faster binding to integrase bearing mutations that render virus resistant to raltegravir. Elvitegravir, another experimental integrase inhibitor, bound to wild-type integrase faster than 572.
Although its own resistance profile is still being characterized, 572 retains activity against certain viruses resistant to raltegravir and to elvitegravir [32, 33] . To further assess activity of 572 against wild-type and mutant integrase, Yoshinaga et al. [31] used two integrase strand-transfer assay methods, one with three washes to remove unbound integrase inhibitor (stringent conditions) and one with no washes (less stringent conditions). Integrase was engineered to carry single or double mutations that make virus resistant to raltegravir and elvitegravir: E92Q, G140S, N155H, E138K/ Q148R, G140S/Q148H and E92Q/N155H.
The 50% inhibitory concentration (IC 50 ) of 572 against wild-type integrase (4.2 nM no wash, 4.8 nM three washes) was equivalent to the IC 50 s of raltegravir (6.4 and 7.5 nM, respectively) and elvitegravir (4.9 and 5.1 nM, respectively). The investigators observed similar trends with addition of the mutations G140S, G140S/Q148H and E92Q/N155H. However, IC 50 s of 572 against the E138K/Q148R mutant (4.2 nM) differed markedly from IC 50 s of raltegravir (66.5 nM) and elvitegravir (104.8 nM).
Time-course experiments showed that 572 and raltegravir bound to integrase slowly and reached steady state by 90 min. 572 bound to the N155H and E138K/ Q148R mutants in a time course similar to that seen with wild-type integrase, and 572 inhibited viral replication of both of those mutants as well as it inhibited wild-type virus. Raltegravir could not fully bind to the N155H and E138K/Q148R mutants, even when Yoshinaga et al. [31] prolonged the preincubation time. As a result, N155H and E138K/Q148R were resistant to raltegravir in a HeLa/CD4-cell assay. Elvitegravir bound to the E92Q and N155H mutants in a time course similar to wild-type binding. However, these mutant integrases were resistant to elvitegravir in the HeLa/CD4-cell assay. The investigators suggested these data indicate that 572 binds to integrase differently from raltegravir and elvitegravir, and that these findings could help explain the activity of 572 against virus resistant to raltegravir and elvitegravir.
Another Resistance Workshop study found that raltegravir-experienced patients screened for a trial of 572 had more evolved raltegravir resistance patterns than in published reports of patients in whom raltegravir failed [34] . Viruses with the greatest resistance to 572, measured as fold-change in susceptibility to 572, had a mutation at integrase position Q148 with two or more other integrase substitutions. That pattern was associated with the longest raltegravir use.
Slow dissociation rate from integrase by S/GSK1349572
The experimental integrase inhibitor S/GSK1349572 (or 572) bound to wild-type integrase and raltegravirresistant integrase longer than raltegravir in an in vitro system [35] . Along with similar earlier work on raltegravir binding characteristics, the findings shed more light on mechanisms of resistance to these strand-transfer integrase inhibitors.
Researchers from Merck (Whitehouse Station, NJ, USA), maker of raltegravir, proposed in 2009 that a 7.3-h raltegravir dissociation half-life from viral integrase/ DNA complexes could explain the strong activity of this antiretroviral [36] . When integrase bore the N155H resistance mutation, the dissociation half-life declined 10-fold to 0.7 h. MK-2048, an experimental Merck integrase inhibitor, had a dissociation half-life of 32 h on wild-type integrase and 4 h on the N155H mutant.
The new work by Shinogi/GlaxoSmithKline (Brentwood, UK) investigators compared raltegravir and 572 dissociation rates from wild-type and mutant integrase over 7 days [37] . The mutations studied all render virus resistant to raltegravir: N155H, Q148H, Q148R, Q148K, and G140S or Q148R plus other substitutions.
With wild-type integrase, 572 had a dissociation half-life of 100.4 h, 10× longer than the 10.1-h dissociation half-life of raltegravir in these experiments. Dissociation half-lives of both integrase inhibitors declined with mutant integrase (Table 3 ). In addition, dissociation half-lives were higher with G140S or Q148R alone than with those mutations plus others.
For all dissociation experiments together, half-lives were 6 to >51× longer with 572 than with raltegravir. The investigators suggested that these long dissociation half-lives could contribute to the activity of 572 against virus resistant to raltegravir.
The study did not examine dissociation rates with T124A, S153Y or L101I mutants, which conferred resistance to 572 in earlier in vitro analyses [37] . Attendees cautioned that findings in cell-free systems such as the one used in this study may not reflect characteristics of these drugs in vivo.
Activity of an antiretroviral meant to increase mutation rate
The deoxycytidine nucleoside analogue KP-1212 (KP-1212 is the biologically active form of the compound labelled KP-1461) is distinctive among antiretrovirals in its intended mode of action, the complete collapse of a viral population by increasing the viral mutation rate. Unlike other antiretrovirals, KP-1212 investigators Mullins et al. [38] proposed this agent may not result in substantial reduction in plasma viraemia before achieving its objective, viral population collapse. These researchers analysed the activity of KP-1212 in 10 antiretroviral-experienced patients who participated in a Phase II trial of KP-1212 and in 10 untreated individuals.
Mullins et al.
[38] cited earlier research to support the hypothesis that viral mutation rates above a critical error threshold result in loss of viral infectivity. For example, only a twofold increase in mutation frequency yielded a collapse in infectivity of lymphocytic choriomeningitis virus [39] . The investigators sequenced 1.0 kb of HIV-1 gag from ≥105 single viral genomes derived from 20 patients at three points: at treatment days 0, 56 and 124 in treated patients and at days 0, 49-78 and 105-147 in the untreated controls.
KP-1212-treated patients were enrolled in a Phase II trial of the drug given at a dose of 1,600 mg twice daily for 124 days. Consistent with thinking about the activity of KP-1212, plasma viraemia did not decline significantly over the course of this study. Plasma viraemia did decrease in a Phase I study that used hand-packed capsules rather than the machine-packed capsules used in the Phase II trial. Continued study of KP-1212 will use an enhanced formulation with increased bioavailability.
This type of in vivo mutation evaluation is complicated, according to Mullins et al. [38] , because mutations may represent three types of base substitutions: silent mutations (in which no amino acid substitutions occur), missense mutations (in which amino acid substitutions do occur) and nonsense mutations (which create a stop codon). Missense mutations (which comprise approximately 70% of a viral population) and nonsense mutations (which comprise about 5%) have a high likelihood of resulting in a defective virus, which will be lost from the viral population. Once lost, they cannot be analysed by gene sequencing.
Private mutations, defined as those not found in multiple viruses, occurred at similar frequencies in treated and untreated individuals at day 0 (P=0.28). Frequency of private mutations increased significantly in treated individuals versus untreated individuals by day 56 (P=0.02) and by day 124 (P=0.001). The spectrum of mutations also differed between treated and untreated individuals, with significantly more A-to-G and G-to-A substitutions in the treated group (P=0.01), and substantially more T-to-C and C-to-T substitutions in the treated group (P=0.09), each as predicted by the proposed mechanism of action of this compound.
Crystallographic analysis of resistance to EFdA
Crystallographic analysis of the NRTI 4′-ethynyl-2-fluoro-2′-deoxyadenosine (EFdA) confirmed that changes at three positions in the polymerase domain, 184, 165 and 142, reduce RT susceptibility to EFdA by affecting both incorporation of the inhibitor and excision of the incorporated analogue [40] .
EFdA is a deoxyadenosine nucleoside analogue with greater activity than zidovudine or tenofovir disoproxil fumarate against HIV-1 in vitro. This novel agent is at least 10× more potent than other NRTIs studied by Marchand et al. [40] The M184V mutation, which confers resistance to lamivudine and emtricitabine, also renders HIV-1 resistant EFdA. In cell culture, M184V yielded 7.5-fold resistance against EFdA. A T165R mutation evolves only after emergence of M184V and together these mutations decreased susceptibility to EFdA 13-fold. The I142V mutation appeared after M184V and T165R, and the three mutations together decreased viral susceptibility to EFdA 21-fold.
Functional studies by Marchand et al. [40] showed that M184V and T165R confer resistance to EFdA by reducing incorporation efficiency of the inhibitor, while I142V makes HIV-1 less susceptible to EFdA by increasing the excision rate of the incorporated analogue [41] . To determine the molecular basis of resistance to EFdA as a result of these mutations, the investigators performed crystallographic studies of RT bearing these mutations.
Crystallography revealed that mutant RT has an overall conformation similar to the wild-type enzyme. However, important changes can be observed at each mutation site. The mutations reposition YMDD (the active site of the enzyme), a change that could explain reduced nucleotide incorporation of the mutant protein and reduced fitness of the corresponding virus. Thus, the displacement probably explains the reduced incorporation of EFdA into the mutant enzyme. While M184V and T165R confer resistance through this discrimination mechanism, I142V appears to confer resistance in an ATP-dependent manner by promoting excision of the incorporated analogue.
Marchand et al. [40] concluded that these molecular findings support both mechanisms, discrimination and excision, and that both are needed to create high-level resistance to EFdA.
Markers of response to entry inhibitors
Clinical trials of the C-C chemokine receptor type 5 (CCR5) antagonists maraviroc, vicriviroc and aplaviroc relied on a phenotypic assay, the original Trofile assay (OTA), to determine whether HIV-1 in patients screened for those studies uses the CCR5 coreceptor, the C-X-C chemokine receptor type 4 (CXCR4) coreceptor, or both. Only exclusively CCR5-tropic virus responds to CCR5 antagonists. An enhanced-sensitivity Trofile assay (ESTA) determined that a small proportion of patients whose virus was initially rated CCR5-tropic when screened with OTA for two of these trials also carried some X4-using virus and thus should have been excluded from the trials.
Because
Genotypic approaches to coreceptor prediction
Sierra et al. [42] found nearly 90% agreement on CCR5 versus CXCR4 use in 10 European labs and one reference centre using the geno2pheno tool to predict coreceptor use with false-positive rate settings of 5% and 10%. This analysis involved samples from 166 randomly selected patients, 118 of whom (71%) were successfully analysed by geno2pheno in both the European labs and the reference lab. The investigators also sent 96 samples for parallel phenotypic analysis by OTA.
These researchers found 88.1% overall between-lab concordance on coreceptor calls with geno2pheno, with no major difference between HIV-1 subtype B samples and other HIV-1 subtypes. Concordance was better with a 5% false-positive rate cutoff. Discrepancies between labs could not be ascribed to low plasma viraemia. Rather, the investigators suggested that differences in primers and procedures may explain such discrepancies.
The investigators noted that in the Cologne RESINA cohort, 23 of 60 patients received maraviroc based solely on genotypic prediction of coreceptor use, and 22 (96%) had a successful virological response. The researchers argued that these RESINA findings support routine clinical use of genotypic coreceptor testing. Among all 60 patients in this RESINA analysis, maraviroc-based therapy was successful in 53 (88%), a result comparable to findings in the Berlin-maraviroc cohort (83 of 100 patients successfully treated).
Of the 96 samples sent for OTA analysis in the 10-lab study [42] , 66 (69%) could be analysed. OTA and geno2pheno coreceptor predictions were concordant in 80.7% of samples with a geno2pheno false-positive cutoff of 10% and in 84.2% with a false-positive cutoff of 5%. HIV-1 RNA level did not significantly influence coreceptor predictions with OTA or geno2pheno. Concordance between genotyping and OTA was better with a 5% false-positive rate cutoff, but German-Austrian guidelines still recommend higher cutoffs to limit the possibility that maraviroc will be prescribed for some patients with X4-using virus.
In a comparison of coreceptor use predictions with OTA and with 454 deep sequencing, Chapman et al. [43] found concordant results in 749 of 889 patients (84%) enrolled in three trials of maraviroc in treatment-experienced patients, MOTIVATE 1 and 2 [44] and protocol A4001029 [45] . Most concordant calls (659, 74% of 889) were R5 by both assays, while 90 (10% of 889) were non-R5 by both assays. Of the 140 discordant coreceptor calls, 15 (11%) were called R5 by 454 sequencing and non-R5 by OTA. The proportion of OTA R5 results that 454 sequencing changed to non-R5 (16%) is similar to the proportion of reclassifications with ESTA in antiretroviral-naive patients enrolling in the MERIT trial [46] . The remaining 125 discordant calls were non-R5 by 454 sequencing and R5 by OTA.
Chapman et al. [43] reported that patients with concordant R5 results had the best virological response (median 24-week decline ~2.5 log 10 HIV-1 RNA copies/ml). Patients with non-R5 results by 454 sequencing had a median 24-week decline of ~1 log 10 HIV-1 RNA copies/ml, regardless of their OTA result. Patients whose virus was called R5 by 454 sequencing and non-R5 by OTA had an intermediate 24-week viral decline in plasma viraemia (~1.5 log 10 HIV-1 RNA copies/ml). In cases of discordance, 454 genotypic tropism results correlated better with response than did OTA results.
Swenson et al. [47] also used 454 deep sequencing to analyse coreceptor use at screening in the MOTI-VATE trials [44] of maraviroc in treatment-experienced patients [47] . The study focused on 184 patients determined to have CCR5-using virus when screened for the trials by OTA assay but whose maraviroc regimen failed virologically (HIV-1 RNA>50 copies/ml). The investigators also used standard sequencing to analyse viral samples upon virological failure.
Coreceptor calls at failure were the same by standard sequencing and OTA in 168 of 184 samples (91%). Both OTA and standard sequencing read virus as non-R5 in 91 samples and R5 in 77. OTA interpreted 14 of 16 discordant samples as non-R5, while standard genotyping interpreted two discordant samples as non-R5. Patients in whom standard genotyping detected non-R5 virus at virological failure did worse clinically than those with R5 virus at failure; they had a smaller median decline in HIV-1 RNA from study entry to week 8 (0.4 log 10 copies/ml versus 2.0 log 10 copies/ml) and a lower increase in CD4
+ T-cells from study entry to week 24 (median 34  cells/mm  3 versus 90 cells/mm   3 ). Deep sequencing with the 454 platform found that 51 of 184 patients (28%) in whom maraviroc failed had non-R5 virus that made up at least 2% of the screening viral population. OTA called the virus R5 in all of these 51 patients. In 63 of 93 patients (68%) with non-R5 virus at follow-up, deep sequencing detected screening V3 sequences that were closely related to failure sequences. Swenson et al. [47] proposed that this finding indicates selection of pre-existing non-R5 virus by maraviroc and rapid outgrowth of this virus, resulting in virological failure. Deep sequencing also determined that non-R5 virus comprised an average 15% of screening viral populations in patients whose maraviroc regimen failed with non-R5 virus. In contrast, patients in whom maraviroc failed with R5 virus had an average 1% of non-R5 virus in screening samples.
Analysis of antiretroviral-experienced patients enrolled in the VICTOR-E1 trial of vicriviroc determined that using ESTA instead of OTA to identify patients with CCR5-tropic virus for study entry would not have improved virological outcomes at 48 weeks [48] . Clonal analysis of HIV-1 V3 sequences from some of these patients yielded evidence that ESTA did not consistently identify CXCR4-using virus in studyentry samples.
The Phase II placebo-controlled VICTOR-E1 trial documented a sustained response to vicriviroc plus a ritonavir-boosted PI and other antiretrovirals in patients with CCR5-using virus who switched from a failing regimen [49] . However, identical Phase III placebocontrolled trials of vicriviroc found no 48-week virological benefit with this CCR5 antagonist [50] , and development of the drug for treatment-experienced patients stopped.
Strizki et al. [48] used ESTA to reanalyse 108 viral samples from patients in whom OTA called virus CCR5-tropic at baseline in VICTOR-E1. ESTA determined that 22 of those pretreatment samples (20%) could use CXCR4 and virological failure occurred in 5 of those 22 patients (23%) during the trial. Vicriviroc also failed in three of six patients whose virus OTA originally rated dual/mixed-tropic at baseline. Excluding those 28 patients with pretreatment X4-using virus from the analysis did not significantly improve the 48 
Mechanisms of coreceptor use and antibody binding
Analysis of HIV-1 V3 sequence signatures showed that V3 determinants beyond the classical positions 11 and 25 correlate significantly with HIV-1 coreceptor use [51] . This work by Svicher et al. [51] also produced evidence that these additional V3 determinants can modulate the HIV-1 gp120 interaction with the CCR5 N-terminus and with the neutralizing antibody 412d; these findings suggest that these V3 determinants can modulate HIV-1 immunogenicity.
Although V3 positions 11 and 25 play critical roles in HIV-1 binding to CCR5 and CXCR4 on CD4 + T-cells, they are not sufficient to explain the mechanisms underlying coreceptor use. The base of the V3 loop interacts directly with the CCR5 N-terminus, an interaction critical for entry of CCR5-using virus into target cells. The V3 base also interacts with some human neutralizing antibodies, such as 412d. Svicher et al. [51] explored V3 determinants that may correlate with CCR5 or CXCR4 use and evaluated the effect of those determinants on the interaction with the CCR5 N-terminus and with 412d.
The investigators focused on HIV-1 RNA obtained from 544 patients infected with HIV-1 subtype B (410 with R5 virus and 134 with X4 virus). They assessed coreceptor use for each sample by interpreting V3 sequences with the geno2pheno coreceptor tool at a false-positive rate setting of 10%. Hierarchical clustering and mutagenic trees were used to define patterns of V3 determinants that correlated with different coreceptor use. In addition, gp120 interactions with the CCR5 N-terminus and 412d antibody were evaluated by docking analysis and molecular-dynamic simulations based on a model described by Huang et al. [52] .
In total, 25 V3 genetic determinants correlated significantly with CXCR4 use, while two determinants correlated with CCR5 use. Twenty of the V3 determinants correlating with CXCR4 lay at positions other than 11 or 25, while one of the determinants correlating with CCR5 use (T22A) did not involve position 11 or 25. Clustering analysis identified clusters of V3 mutations associated with CCR5 or CXCR4 use. Accumulation and clustering of V3 mutations led to a progressive increase in the ability of HIV-1 to use either CCR5 or CXCR4.
T8A/I mutations in chronically infected antiretroviralnaive patients correlated with lower CD4 + T-cell count but not with viraemia, a result suggesting that this mutation may interfere with HIV cytopathicity. Certain V3 determinants associated with CXCR4 use and localized in the V3 base (N5Y, N7K, S11R, S11R/N7K, E25R and Q32K) can reduce gp120 binding affinity for the CCR5 N-terminus. N7K increased the distance between V3 position 7 and sulphotyrosine at CCR5 position 14, which is crucial for binding to gp120; the increased distance abrogated the interaction between these two residues. Certain V3 determinants (S11R, N7K and E25D) associated with use of either CCR5 or CXCR4 may also increase the binding affinity for the neutralizing antibody 412d, an interaction suggesting their ability to modulate HIV-1 immunogenicity.
Svicher et al. [51] proposed that the kind of data collected in this analysis can help optimize genotypic tropism testing and may have implications for designing vaccines and new entry inhibitors.
Pathways and barriers to CXCR4-mediated HIV-1 entry
Analysis of HIV-1 V3 sequences in patient viral isolates demonstrated that a change from CCR5 to CXCR4 coreceptor use requires multiple and sequential amino acid changes and that the effect of individual V3 substitutions on CXCR4 use is subtle and backbone dependent [53] .
Huang et al. [53] undertook this study because evolutionary pathways leading to efficient CXCR4 use are poorly defined, even though genetic determinants in the V3 loop, notably at positions 11 and 25, are firmly associated with CXCR4-mediated viral entry. Absence of a potential N-linked glycosylation site at position 6-8 also plays a role in CXCR4 use.
The investigators analysed 35 viral population samples containing unambiguous V3 sequences with amino acid substitutions at positions 11 or 25 and lacking the potential N-linked glycosylation site at position 6-8. In addition, they performed clonal analysis of viral samples from 12 patients containing mixed amino acid sequences at this position. The researchers used site-directed mutagenesis to introduce single amino acid substitutions into the V3 region (S11K, S11R, E25K, E25R and N6Q) of three CCR5-using clones, and to introduce R11S reversions into two dual-tropic clones.
Position 11R substitutions in env clones were strongly associated with (but not essential for) CXCR4 use. Multiple compensatory mutations were required to overcome reductions in infectivity associated with position 11 substitutions. Position 25K/R substitutions or substitutions that result in loss of potential N-linked glycosylation sites at position 6-8 contributed to CXCR4 use but required additional substitutions to confer efficient use of that coreceptor. CXCR4 use of env clones containing potential N-linked glycosylation sites at position 6-8 varied within different env backbones.
Persistence, reservoirs and elimination strategies
Experimental agents to activate latently infected CD4 + T-cells
Attempts to eradicate HIV-1 from humans have failed because viral DNA integrates in CD4 + T-cells that go into a resting stage in which they become invulnerable to antiretroviral therapy. Attempts to activate these cells to expose virus to antiretrovirals have failed so far, partly because of the toxicity of the agents used. Wightman et al. [54] evaluated four histone deacetylase inhibitors (HDACi) being used or studied in patients with cancer. HDACi enhance acetylation of histones bound to the HIV-1 long terminal repeat and thereby promote transcription of latently infected cells.
The investigators exposed purified resting CD4 + T-cells to an HIV-1 lab strain to establish latent infection. Then they exposed these latently infected cells and three chronically infected cell lines to the HDACi Vorinostat (SAHA, a pan-HDACi), Panabinostat (LBH589, a pan-HDACi), Entinostat (MS-275, an HDAC1-specific HDACi), MCT-3 (a class I and II HDACi), phorbol myristate acetate (a positive control) or DMSO (a negative control). Among these agents, SAHA is the only licensed drug. The researchers quantified induction of HIV-1 transcription by measuring HIV-1 RT in supernatants. All HDACi induced HIV-1 expression in all three cell lines and all four agents were toxic (Table 4) . Wightman et al. [54] recorded the greatest RT activity with MS-275 in the ACH2 cell line, followed in decreasing order by MCT-3, SAHA and LBH589. HDACi induction of HIV-1 expression was both dose-and time-dependent. Median toxicity in ACH2 cells measured as 50% effective concentration (EC 50 ) was 0.07 µM with LBH589, 0.42 µM with SAHA, 0.65 µM with MS-275 and 1.58 µM with MCT-3.
The investigators next used their T-cell model to evaluate the activity of these four agents at the lowest concentration at which they were effective in the cell lines, 0.5 µM. All four HDACi reversed latency in primary CD4 + T-cells at this concentration. In primary T-cells, potency was greatest with MCT-3, followed by SAHA and LBH589, with MS-275 the least potent.
Toxicity in primary CD4
+ T-cells was low with MCT-3, SAHA and MS-275, and high with LBH589.
Wightman et al. [54] concluded that their primary T-cell latency model is a robust method for evaluating the potency and toxicity of HDACi. They are now assessing HDACi occupancy of the HIV-1 long terminal repeat in this model, which is also important in establishing the value of these agents in activating latent cells in patients with HIV-1 infection.
Low HIV-1 diversity after viraemia rebound HIV-1 populations in patients who interrupted long-term suppressive antiretroviral therapy diverged genetically by an average 0.3% from pretreatment viral populations in a small study of patients treated for 2 to 15 years [55] . The finding indicates that HIV-1 population diversity is maintained throughout years of suppressive antiretroviral therapy and suggests that HIV-1 persists during therapy in long-lived cells infected before therapy began.
To evaluate the effect of long-term suppressive antiretroviral therapy on genetic diversity in plasma virus, Kearney et al. [55] analysed HIV-1 in samples collected before and during long-term viral suppression by eight patients, all of them infected with HIV-1 subtype B. No-one had taken antiretrovirals before starting this suppressive regimen. Duration of infection ranged from 1 to 15 years and duration of treatment from 3 to 15 years. The investigators used singlegenome sequencing to analyse sequences in three ways: diversity determined by allele frequencies (average pairwise difference), population structure determined by phylogenetic relationships of subpopulations and divergence determined by a shift in populations over time (intersample average pairwise difference).
Kearney et al. [55] found no obvious change in HIV-1 diversity measured by average pairwise difference during long-term suppression (pre-antiretroviral versus on-treatment diversity difference; P=0.3). Phylogenetic analysis revealed emergence of populations of identical sequences in on-treatment virus in seven of eight patients.
The researchers sampled virus from five patients before therapy began and after viral rebound following self-initiated treatment interruption. In these subtype-B-infected individuals, treatment duration ranged from 2 to 15 years and time between rebound and last undetectable HIV-1 RNA level ranged from 1 to 3 months. This analysis disclosed no significant change in HIV diversity from pretreatment sequences to rebound sequences (P=0.4). In four of these five patients, sequences that emerged during rebound were similar to pretreatment sequences. Kearney et al. [55] proposed that the restricted diversity after years of suppressive antiretroviral therapy suggest either slow loss of chronically infected cells or clonal expansion of one or more chronically infected cells. The researchers suggested that lack of divergence between pretreatment virus and rebound virus implicates long-lived cells infected before therapy as the source of virus in rebound viraemia.
Monotypic HIV-1 DNA is common during antiretroviral therapy
Monotypic HIV-1 DNA (a group of identical viral sequences comprising ≥5% of sequences) became common during antiretroviral-induced suppression of HIV-1 RNA in plasma in a study of six adolescents [56] . This finding in peripheral blood mononuclear cells (PBMCs) and sputum cells suggests that proliferation of HIV-1-infected cells may sustain infection during suppressive therapy.
Wagner et al. [56] noted three proposed mechanisms of HIV-1 persistence during suppressive antiretroviral therapy: long half-life of latently infected cells, low-level viral replication and proliferation of HIV-1-infected cells. If the third mechanism is an important factor in persistence of infection, the investigators hypothesized that identical (monotypic) HIV-1 DNA sequences should increase during successful therapy. To address that hypothesis, they sampled PBMCs and sputum cells from six patients taking a successful regimen for a median of 9.5 years (range 8 to 11). Using single-genome amplification, they analysed env and RT sequences collected before therapy began and more than twice during treatment.
The median number of env sequences per patient was 124 (16% pretreatment and 32% from sputum) and the median number of RT sequences was 146.5 (17% pretreatment and 34% from sputum). Monotypic HIV-1 DNA increased by a median of 2% yearly and a mean of 6% yearly in the specimens studied. Prevalence of monotypic env and RT sequences increased significantly in on-treatment samples compared with pretreatment samples (P=0.05). Of the total 867 env sequences analysed, 124 (14%) were monotypic. The investigators found that only two of the 743 non-monotypic env sequences (<1%) were synonymous with the monotypic sequences, a result arguing against replication of a unique viral variant.
On the basis of these findings, Wagner et al. [56] proposed that proliferation of cells with integrated HIV-1 DNA may be an important mechanism in longterm HIV-1 persistence during effective antiretroviral therapy. They noted, though, that this type of analysis cannot establish whether HIV-1 DNA is viable.
Most HIV-1 DNA in PBMCs lies in non-gut-homing CD4s
Most of the HIV-1 reservoir in PBMCs resides in nongut-homing memory CD4 + T-cells, which circulate through secondary lymphoid tissue but not through gut-associated lymphoid tissue (GALT), according to results of a 12-patient study [57] . Recent research indicates that early HIV infection can lead to massive infection of CD4 + T-cells in GALT [58] , which may result in ongoing leakage of microbial products from the gut and chronic immune activation. Other work suggests that GALT may be a critical latent reservoir for HIV [59] . Because direct study of HIV in GALT is difficult, Koelsch et al. [57] examined specific CD4 + T-cell subsets in the peripheral circulation. The investigators also evaluated T-regulatory CD4 + T-cells (Tregs), which increase in GALT during chronic HIV infection. Earlier work by the current investigators found that most HIV-1 DNA can be found in CD38 dim CD127 high resting CD4 + T-cells [60] . The new study involved eight patients with early, untreated chronic HIV infection, two with primary HIV infection, and two with treated HIV infection and HIV-1 RNA<50 copies/ml in plasma [57] . Compared with healthy HIV-negative controls, the patients with chronic untreated HIV infection had lower levels of gut-homing memory CD4 + T-cells (7% versus 14%) but not non-gut-homing memory cells (48% versus 42%). Levels of memory Tregs and CD127 high memory cells did not differ significantly between the chronic HIV group and healthy adult controls.
In the patients with primary HIV infection, more than 70% of HIV-1 DNA was found in α4β7-(nongut-homing) memory cells, a result reflecting findings in the group with chronic untreated HIV infection. Combining results from all three patient groups studied, Koelsch et al. [57] found approximately 80% of HIV-1 DNA in α4β7-(non-gut-homing) memory cells. The investigators concluded that most HIV-1 DNA in memory CD4 + T-cells during primary, chronic and treated HIV infection can be found in non-gut-homing cells. Caution must be exercised in interpreting these results because of the small size of the patient sample and because the analysis involved T-lymphocytes collected from peripheral blood, not gut tissue.
Application of new sequencing techniques
Development of new techniques to quantify and characterize drug-resistant virus has furthered the understanding of resistance in patients infected with HIV. This Resistance Workshop offered several presentations on deep-sequencing platforms that detect lowfrequency viral populations not revealed by standard sequencing. In patients with HIV infection, detection of these minor variants could prove particularly important in three scenarios: cross-resistance within the same antiretroviral class, untreated individuals with 'occult' transmitted resistance mutations and minority CXCR4-using variants [61] . Reviewing these techniques at the Workshop, Shafer [61] characterized them as powerful research tools that still pose challenges in establishing sensitivity and specificity, and in interpreting data from studies using these techniques. He proposed that those challenges should be addressed by development of improved methods for sample preparation. As these challenges are met, Shafer [61] suggested that deep sequencing would find clinical use.
Minority mutations in South African trial participants
Studies with deep-sequencing technologies in antiretroviral-naive patients in high-income countries have shown that these technologies detect an increased number and frequency of mutations. At the Resistance Workshop, Wallis et al. [4] offered the first deep-sequencing analysis of transmitted resistance in a South African cohort recently infected with HIV-1 subtype C.
The investigators focused on 60 viral samples from female participants in a multicentre randomized trial. At study entry, all participants had been HIV-1 positive for <6 months; their median HIV-1 RNA level stood at 4.5 log 10 copies/ml. All 60 samples were analysed by standard population-based sequencing and deep sequencing. For deep sequencing, Wallis et al. [4] used the WHO 2009 surveillance list to identify mutations [9] . They counted protease and RT mutations present in more than 1,000 reads and confirmed them in both the forward and reverse directions.
Among all 60 women, standard sequencing detected transmitted resistance mutations (G190A in RT) in 2 (3%). Deep sequencing detected mutations at a frequency >1% in 21 viral isolates (35% of 60) and at a frequency >0.5% in 39 women (65% of 60). Nine protease mutations (M46I, M46L, I47A, F53L, V82A, N83D, I84V, I85V and N88S) could be detected at a frequency >0.5%, and two mutations (V82A and N83D) could be detected at a frequency >1.0%. A total of 14 RT mutations could be detected at a frequency >0.5% (L100I, K101E, G190S, G190E, G190A, P225H, K65R, D67N, D67G, K70R, F77L, M184I, K219E and K219R), including K65R in 70% of isolates. Nine of these mutations (L100I, G190A, P225H, K65R, D67N, K70R, F77L, M184I and K219E) could be detected at a frequency >1%.
Wallis et al. [4] cautioned that their analysis cannot determine whether these mutations (especially the highfrequency K65R) were actually present in these patients as a result of transmitted drug resistance or whether their detection results from amplification and sequencing errors. Earlier research indicates that K65R can evolve more readily in patients infected with HIV-1 subtype C than in those infected with subtype B [62] [63] [64] .
Deep sequencing detects low-level K65R in subtype C
Deep sequencing by the 454 Life Sciences system (454 Life Sciences) detected low levels of the K65R RT mutation in patients infected with HIV-1 subtype C more often than in patients infected with other subtypes [65] . The clinical implications of this finding remain unclear at this point.
Previous research found that subtype C virus may be more likely than other subtypes to harbour K65R variants, possibly because of template-dependent mutagenesis [63] . To evaluate the frequency and effect of K65R mutations in diverse HIV-1 subtypes, Kozal et al. [65] planned this study with 454 deep sequencing to search for minority populations of K65R in antiretroviral-naive individuals and to assess the effects of antiretroviral exposure on K65R levels.
Among 411 antiretroviral-naive individuals, deep sequencing detected K65R at levels ≥1% in four (1%), including two patients with subtype C, one with subtype B, and one with subtype BF. All K65R mutations in these four patients were linked to other NRTI and NNRTI resistance mutations, and that linkage suggested these were transmitted resistance mutations.
Among 147 antiretroviral-naive patients whose virus was sequenced to detect mutants comprising <1% of the viral population, 13 (9%) with mean plasma viraemia of 212,215 copies/ml had K65R. Ten of these patients had subtype C, compared with two who had subtype B (P<0.001), and one with recombinant AE. All 13 patients began treatment with tenofovir disoproxil fumarate/emtricitabine plus a ritonavir-boosted PI. In total, 8 of these 13 patients with K65R (7 with subtype C) did not have virological failure after 2 years of antiretroviral therapy. In 5 of the 13, therapy failed virologically, including one patient with subtype B whose virus was not analysed by deep sequencing at failure. Of the remaining four patients with virological failure, one had subtype B and three had subtype C. Table 5 summarizes virological and K65R frequency findings in these four individuals. Because K65R frequency in these four patients remained stable through antiretroviral failure, Kozal et al. [65] proposed that other active components of their regimen may have prevented further selection of K65R or that K65R detection may have resulted from viral or assay polymerization errors, especially with subtype C. The investigators concluded that the implications of K65R variants detected at a frequency <1% in patients who begin tenofovir disoproxil fumarate/ emtricitabine plus a boosted PI remain to be determined since most of these variants occurred at very low levels that did not increase after antiretroviral exposure.
In a separate study on the prevalence and clinical significance of mutations detected by 454 deep sequencing, these same investigators found similar rates of transmitted resistance mutations in patients infected with subtype B and non-B HIV-1 [66] . Transmitted mutations did not affect 48-week virological response among patients starting a boosted PI regimen, but a small subset of patients with extensive NRTI transmitted mutations experienced virological failure.
It is important to note that work reviewed by Shafer [61] and carried out in his lab [67] found strong evidence that increased rates of K65R in subtype C viruses resulted from PCR error with deep sequencing.
PCR recombination error rate reduced in deepsequencing system
Because linkage analysis of mutations can be compromised in the 454 Life Sciences deep-sequencing system by PCR-based recombination, Shao et al. [68] devised and tested a method to reduce recombination. The investigators mixed two clones in a 50:50 ratio, including one wild-type clone and one containing seven linked RT mutations: M41L, K65R, D67W, K70R, L74V, L100I and K103N. They amplified this mixture under standard PCR conditions and under low-recombination conditions (1 µM primers, 400 µM deoxynucleotide triphosphates, 2.3 mM MgCl2, 1× Taq Gold buffer and 5 units Taq Gold; 95°C for 15 min followed by 25 cycles at 95°C for 15 s, 51°C for 30 s and 68°C for 1 min 30 s). The researchers then sequenced the products by 454 deep sequencing.
Among sequences from amplicons produced under standard PCR conditions, 11.65% were recombinants from template crossovers between wild-type and mutant plasmids. Among sequences from amplicons produced under low-recombination conditions, 0.43% were recombinants, a 27-fold reduction compared with standard conditions. Point error rates were 0.123% ±0.150% under standard conditions and 0.084% ±0.125% under low-recombination conditions (P<0.01). A large fraction of point errors occurred during the PCR step.
Shao et al. [68] counted 75 crossover patterns resulting from standard PCR conditions and 20 from low-recombination conditions. Sequence error rate was slightly lower under low-recombination conditions (0.8%) than under standard conditions (0.11%), perhaps because of the reduced cycle number.
Single transmitted mutation may not signal more extensive resistance
Most resistance mutation profiles in antiretroviral-naive individuals consist of a single detectable mutation [69] . Whether these so-called singletons represent a wider population of mutations that faded below detection limits after primary infection, or whether they are true singletons, remains unknown.
To address this question, Pingen et al. [70] studied 10 patients with HIV-1 harbouring a single detectable mutation before antiretroviral therapy. The investigators used 454 Life Sciences deep sequencing to analyse viral populations in these patients, who were diagnosed from 2003 through 2008. Plasma viraemia in each person was above 100,000 HIV-1 RNA copies/ml, and each carried virus bearing a single RT mutation detectable by standard sequencing: M41L, T69N, M184V, T215E (in two) T215L, T215S (in three) and K219Q. Based on these genotypes, all patients began an appropriate regimen consisting of an NNRTI or a ritonavir-boosted PI plus tenofovir disoproxil fumarate and emtricitabine.
Deep sequencing disclosed low-frequency mutations in only 1 of the 10 patients. In this man with T69N detected by standard population sequencing, deep sequencing detected T69A (frequency 2.0%), T69N (frequency 11.7%), T69D (frequency 2.6%) and K103N (frequency 7.5%). Because standard sequencing missed the NNRTI-related K103N mutation in this patient, he started an efavirenz-containing regimen, which failed virologically. This patient reported poor adherence to his regimen. All other patients reached and maintained an HIV-1 RNA level below 50 copies/ml.
Pingen et al. [70] concluded that single mutations detected in antiretroviral-naive individuals may usually represent transmission of true singletons, but they called for further research to determine the implications of singletons, especially atypical variants, in choosing an initial antiretroviral regimen.
A 10,458-patient multicohort study found that transmitted resistance mutations were associated with a worse virological response after 1 year of an initial regimen if that regimen included ≥1 antiretrovirals against which HIV-1 had at least low-level resistance [71] . Among patients beginning treatment with two NRTIs plus one NNRTI, those with ≥1 mutations (by standard sequencing) but predicted to have a fully active regimen (by the Stanford algorithm) had more than a doubled risk of virological failure than patients with no detectable resistance mutations (hazard ratio 2.3, 95% CI 1.2-4.6; P=0.02). The investigators speculated that this finding may mean some patients were infected with minority mutant populations not detected by standard sequencing.
Eleven-site analysis finds agreement on deepsequencing results
An 11-centre comparison of resistance mutation analysis by 454 Life Sciences deep sequencing found good correlation between sites and 100% concordance with major Stanford Database mutations reported by standard HIV-1 sequencing [72] . The investigators noted that use of deep sequencing remains complex and needs to be simplified through automation.
In total, 11 labs in Western Europe and southern Africa compared performance of the 454 Life Sciences GS FLX System (454 Life Sciences) with standard population-based sequencing in detecting resistance mutations in HIV-1 protease and RT. The analysis involved 17 HIV-1 subtype B samples from patients with plasma viraemia ranging from 113,000 to 573,000 HIV-1 RNA copies/ml. Before the study, Simen et al. [72] identified 10 variants expected (based on 454 sequencing) to be found across the range of frequencies from 0% to 100%, with three negative control variants expected to have a frequency of 0%.
The analysis revealed that deep sequencing detected 100% of mutations detected by standard sequencing with a Stanford Database score ≥5. Deep sequencing also detected all variants detected by standard sequencing with a Stanford Database score <5. Deep sequencing proved accurate even at frequencies well below those detected by standard population sequencing. The 10 preselected variants were consistently found across sites with deep sequencing.
Simen et al. [72] maintained that site-specific problems with 454 deep sequencing can be resolved because of the high quantitative consistency of results. Problems involved pipetting, incorrect platelayout protocols, and use of two incorrectly manufactured plates to generate amplicons. The investigators recommended primer redesign of the next-generation primer set and coverage of all relevant HIV-1 subtypes. Workflow could be simplified by automation.
Mechanisms of HIV drug resistance
Binding affinity differences among three PIs at I50 position Mutations at HIV-1 protease position I50 affect susceptibility to three PIs, amprenavir, atazanavir and darunavir. However, resistance to the three PIs differs depending on the substitution at that codon: I50V confers resistance to amprenavir and darunavir, while I50L confers resistance to atazanavir.
To evaluate the molecular basis for this difference, Bandaranayake et al. [73] determined binding thermodynamics of amprenavir, atazanavir, and darunavir to wild-type protease and to the I50V and I50L mutant variants. The investigators solved and analysed crystal structures of each PI in complex with wild-type protease, I50V, and I50L, comparing each mutant-inhibitor complex to the corresponding wild-type-inhibitor complex to assess the effect of residue 50 substitution on inhibitor binding.
Most of the changes in binding affinity were relatively small. The I50V variant had twofold weaker affinity to amprenavir and 17-fold weaker affinity to darunavir (the 17-fold reduction in affinity to darunavir did not significantly affect binding because of the high innate affinity of darunavir). In contrast, the I50V variant had an eightfold stronger binding affinity for atazanavir than for wild-type protease. Compared with wildtype, the I50L variant had threefold weaker affinity for atazanavir and twofold weaker affinity for darunavir. Compared with wild-type, binding of the I50L variant to amprenavir improved threefold.
Crystal structure analysis of the three PIs in complex with wild-type and the I50V or I50L mutant disclosed no significant changes in hydrogen bonding patterns that might explain the affinity changes noted above. However, the I50V mutant lost favourable van der Waals contact with amprenavir and darunavir but did not disrupt binding with atazanavir. The I50L mutant lost favourable van der Waals contact with atazanavir, but not with amprenavir or darunavir. Bandaranayake et al. [73] proposed that the observed changes in van der Waals contacts between the wild-type and mutant complexes may contribute to the differing PI susceptibilities seen in the resistance patterns.
Further insights on favoured K65R in subtype C HIV-1
Extending their earlier work, Coutsinos et al. [74] found evidence that evolution of the K65R mutation in HIV-1 subtype C is template-specific and enzyme-independent, and that the underlying mechanism may be dislocation mutagenesis (correct nucleotide incorporation into a misaligned template/primer followed by realignment to create a mismatch).
Prior research by the Wainberg lab determined that the K65R mutation in HIV-1 RT arises more easily in subtype C virus than in subtype B, apparently because silent polymorphisms at RT codons 64 and 65 cause the RT enzyme to pause more frequently at the location of K65R development in subtype C [62] [63] [64] . To isolate the precise mechanism promoting K65R in subtype C virus, Coutsinos et al. [74] used gel-based nucleotide extension assays to analyse patterns of DNA synthesis in recombinant subtype C and B RT enzymes [74] . They used various primers and templates from subtype B and C HIV-1 to evaluate primer-dependent and primer-independent rates of K65R-containing transcript production.
A higher proportion of transcripts containing the mutation responsible for K65R were produced on the subtype C template than on the subtype B template when the investigators assessed production of the mutation in either a primer-dependent manner (68% versus 40%; P<0.05) or a primer-independent manner (40% versus 15%; P<0.05). Subtype origin of RT did not affect these results. With a subtype C template, but not a subtype B template, Coutsinos et al. [74] observed a double-banding pattern of DNA synthesis characteristic of dislocation mutagenesis.
Coutsinos et al. [74] proposed a five-step process for K65R development in subtype C HIV-1: DNA synthesis approaches the end of the homopolymeric region at codon 65, primer/template dislocation, correct nucleotide incorporation into a misaligned primer/template, primer/ template realignment and DNA synthesis continues normally to produce K65R. This process was observed only on the subtype C template and yielded only K65R.
Envelope design of 'resistance-resilient' PIs
Nalam et al. [75, 76] presented data on 10 HIV-1 PIs engineered to take advantage of these investigators' substrate envelope hypothesis: HIV-1 PIs that fit within the overlapping consensus volume of the substrates are less likely to be susceptible to drug-resistant mutations because a mutation affecting such inhibitors would simultaneously affect the processing of substrates. Earlier work by these investigators and others showed that mutations conferring resistance to PIs alter PI binding but do not significantly affect substrate recognition and cleavage. PI resistance mutations occur where an inhibitor protrudes beyond the substrate envelope and contacts protease.
Nalam et al. [75, 76] synthesized 10 PIs specifically designed to fit within the substrate envelope. They used enzymatic and calorimetric studies to test these candidates for inhibitory activity against wild-type HIV-1 and clinically relevant multidrug-resistant variants. The investigators determined the crystal structures of these agents in complex with wild-type HIV-1 protease. Monogram Biosciences (South San Francisco, CA, USA) used the PhenoSense assay to evaluate the activity of these PIs against resistant virus.
Crystal structures of the 10 inhibitors bound to HIV protease showed that they bound very similarly and fit tightly into the HIV-1 envelope. Binding affinities of these experimental PIs to resistant variants were tighter than affinities of nine licensed PIs. The 10 novel PIs bound with single-digit picomolar affinity to wild-type protease. These newly synthesized PIs had greater activity than darunavir against a Monogram Biosciences panel of 17 wild-type and resistant viruses, with EC 50 s frequently in the subnanomolar range.
Nalam et al. [75, 76] proposed that use of the substrate envelope to complement current drug design techniques could permit design of inhibitors less susceptible to drug resistance for many quickly evolving diseases. The investigators acknowledged that tight binding to a substrate target is only one of several characteristics that drug designers should aim for.
Resistance to HBV and HCV inhibitors
Infection with HBV or HCV affects hundreds of millions of people worldwide. Because the hepatitis viruses and HIV share transmission routes, coinfection with HIV and HBV or HCV is common. As licensed and experimental agents for HBV and HCV proliferate, understanding viral resistance and cross-resistance to these agents assumes ever-greater importance.
Chronic HBV infection kills 2 million people every year. Worldwide, HBV is the second most potent carcinogen after tobacco. However, HBV research began to suffer from lack of funding when a preventive vaccine became available [77] . Newer RT inhibitors for HBV are tenofovir disoproxil fumarate, entecavir and telbivudine, but Locarnini [77] sees no novel 'blockbuster' drugs for lamivudine-or adefovir-experienced patients (Table 6) .
Resistance-related similarities between HBV and HIV-1 are greater than those between HCV and HIV-1. However, one notable difference between HBV and HIV-1 is the strong conservatory restraint on the HBV genome, which makes resistance to HBV much less frequent than resistance to HIV-1.
Unlike HBV and HIV-1 infection, HCV infection can be cured in some patients with current agents, pegylated IFN plus RBV (PEG-IFN/RBV). However, viral clearance is more difficult to attain in patients coinfected with HIV-1. Several agents under development directly inhibit HCV, including NS3/4A PIs, nucleoside/nucleotide and non-nucleoside inhibitors of RNA-dependent RNA polymerase, inhibitors of HCV-encoded nonstructural protein 5A, and cyclophilin inhibitors. Pawlotsky [78] stressed that the goals of developing these agents include better response rates, shorter treatment duration and better tolerance while still aiming to cure HCV, not merely to suppress replication.
Although several speakers noted similarities between resistance to HIV-1 and resistance to the hepatitis viruses, they also cautioned that not everything learned about HIV-1 resistance will apply to HBV or HCV. Several Workshop presentations focused on HBV and HCV resistance, often in studies of investigational agents.
Emergence of resistance and potential for immune escape of HBV genotypes
An exhaustive analysis of HBV sequences from thousands of antiviral-naive and experienced patients with one of seven HBV genotypes yielded evidence that HBV genetic barrier to resistance and the overlapping structure of the HBV genome act synergistically to modulate HBV resistance to antivirals and immune escape [79] . This is the first study to address HBV genetic barrier to resistance or immune escape, calculated as the sum of nucleotide transitions (score =1) and/or nucleotide transversions (score =2.5) required for the evolution to any drug-resistance or immune-escape mutation.
This study by Svicher et al. [79] The genetic barrier to resistance varied according to the type of drug resistance mutation: the genetic barrier for primary mutations (A181T/V, A194T, M204V/I and N236T) was significantly lower than the barrier observed for secondary mutations (L80I/V, I169T, V173L, L180M, T184G/S, Q215S, S202I and M250V; median score 1.0 versus 2.5; P=0.011).
With two exceptions, evolution of HBV resistance to antivirals followed the pathway with the lowest genetic barrier. The exceptions to this rule, RT mutations M204I and A181S, may be explained by the overlapping of RT and HBsAg genes in the HBV genome. For example, the M204I mutation can result from the transition ATG to ATA (with a low genetic barrier) or from the transversion ATG to AAT or ATC (with a high genetic barrier). Although the ATA substitution is associated with a low genetic barrier, it causes a stop-codon in HBsAg position sW196, which is not compatible with viral replication. Therefore, the transversion substitutions are preferred for development of M204I and are commonly detected upon virological failure of lamivudine.
The genetic barrier for development of HBsAg mutations involved in immune escape varied among HBV genotypes. Genotypes A and G were more prone to immune escape mutations sT114r and sG130N than were other genotypes. Asparagine (N) at HBsAg position 131, which is associated with vaccine escape in vitro, is the wild-type amino acid in genotypes A and G.
Svicher et al. [79] proposed that, taken together, their results support the paradigm of constrained HBV evolution, which holds that the overlap between RT and HBsAg genes can limit the genetic variability that HBV can tolerate. The investigators postulated that the different immune escape potential of different HBV genotypes can have important effects on disease progression, vaccine strategies and correct HBsAg detection.
Selection and avoidance of HCV resistance
Successful antiretroviral therapy for HIV-1 infection rests on the principle that inhibiting viral replication with a combination of drugs prevents emergence of resistant virus. To determine whether the same principle applies to anti-HCV therapy, Lam et al. [80] assessed the effect of combination anti-HCV agents on emergence of resistance in HCV genotype 1b replicon cells. The investigators tested two combinations: the HCV NS3/4A PI VX-950 plus the NS5B non-nucleoside inhibitor HCV-796 (development of HCV-796 has been halted because of hepatotoxicity) and two NS5B nucleotide inhibitors, PSI-7977 and PSI-352938.
HCV had a 3.8-and 2.9-fold change in susceptibility (measured as change in EC 50 ) to VX-950 and HCV-796, respectively, by day 21 of the selection experiment. Resistance to VX-950 increased to 11.4-fold by day 46 and to >30-fold by day 56. Resistance to HCV-796 increased to 16-fold by day 46 and to 22.5-fold by day 56. Sequencing revealed the NS5B polymerase mutation C445F and several NS3 protease mutations (F43S, A156S/T and V170A) that conferred resistance to HCV-796 and VX-950. With the two NS5B nucleotide inhibitors the overall EC 50 changed only approximately threefold after 120 days in the selection experiments.
Lam et al. [80] proposed that combinations using complementary NS5B nucleotide analogues could erect a significantly higher barrier to resistance than is possible when combining an HCV PI with a non-nucleoside. The investigators noted that the replicon system is not a perfect model of resistance evolution in humans infected with HCV.
HCV resistant to investigational PIs, including boceprevir, telaprevir, ITMN-191, BILN-2061 and TMC435, has emerged in replicon studies and clinical trials. Unlike HIV-1 PIs, HCV NS3/4A PIs can lose activity after emergence of single mutations at certain sites (A156 and R155). To address this potential clinical problem, Romano et al. [81] assessed the balance between substrate recognition by NS3/4A protease and evolution of resistance in x-ray crystallographic studies.
The investigators crystallized peptides corresponding to viral cleavage products (4A4B, 4B5A and 5A5B) in complex with the inactive protease domain of NS3/4A. They also solved the crystal structure of NS3/4A protease in complex with ITMN-191, an HCV PI they had synthesized. The researchers then performed a structural analysis to investigate binding of ITMN-191, boceprevir, and TMC435 relative to NS3/4A cleavage products.
Analysis of the cleavage product complexes revealed a conserved substrate envelope, which Romano et al. [81] defined as a consensus volume shared by three of four peptides. ITMN-191, boceprevir and TMC435 all protruded extensively from the substrate envelope, contacting the critical A156 and R155 resistance sites.
Mutations conferring high resistance in clinical studies occurred where these PIs extended beyond the substrate envelope (this finding fits with the investigators' hypothesis that viral resistance occurs when mutations selectively weaken target affinity for an inhibitor without significantly altering biological function of the target). The investigators also found that an alternative conformation of R155 stacks against the aromatic rings of ITMN-191 and TMC435. A hydrogen bond with the D168 site stabilized these interactions; mutations at D168 can confer resistance to ITMN-191 and TMC435. Romano et al. [81] concluded that the principles of substrate envelope and inhibitor interaction they developed in studying HIV-1 PIs [76] also apply to resistance of HCV NS3/4A PIs.
Resistance to investigational anti-HCV agents
Telaprevir is an HCV NS3/4A PI in Phase III trials with a resistance profile marked by the V36A/M, T54A, R155K/T and A156S/T/V mutations in NS3 [82] . In a Phase II trial of telaprevir involving patients in whom PEG-IFN/RBV had failed (PROVE 3), telaprevir plus PEG-IFN/RBV yielded a greater sustained virological response (SVR) rate than two control regimens [83] . Bartels et al. [83] reported that, among prior non-responders, SVR rates were 39% among patients taking telaprevir plus PEG-IFN/RBV for 12/24 weeks, 38% for those taking this regimen for 24/48 weeks, 11% for those taking telaprevir plus PEG-IFN (but not RBV) and 9% among those taking PEG-IFN/RBV without telaprevir. Respective response rates among prior relapsers were 69%, 76%, 42% and 20%.
In PROVE 3, virological failure with a telaprevircontaining regimen was usually associated with V36M plus R155K, a mutation combination observed only in patients with genotype 1a HCV. In this trial and others, A156V/T mutations were associated with higher-level resistance, while lower-level resistance was seen with V36A/M, T54A, R155K/T or A156S.
Analysis of six HCV genotype-1-infected patients with breakthrough viraemia or post-treatment relapse in the Phase II PROVE 2 trial of telaprevir plus PEG-IFN with or without RBV showed that a complex mixture of resistant variants replaced wild-type virus in all cases [84] . In addition to known telaprevir resistance mutations, other amino acid substitutions emerged. Three-dimensional modelling suggested that none of these additional substitutions affected telaprevir binding to NS3 protease, except perhaps T42S and A40T. These additional changes did not further reduce susceptibility to telaprevir in a replicon-based phenotypic assay, a finding suggesting that these substitutions improve fitness of resistant variants bearing the major telaprevir-associated mutations. V36C, a novel mutation at a known resistance position, emerged in one patient who stopped telaprevir plus PEG-IFN/RBV and increased the IC 50 8.6-fold.
The R155K mutation in HCV genotype 1a protease persisted for months after failure of MK-7009, an investigational inhibitor of HCV NS3/4A protease, in a Phase IIa trial [85] . This double-blind, placebo-controlled trial randomized 94 patients with chronic HCV infection to PEG-IFN/RBV plus placebo or to one of four MK-7009 doses for 4 weeks: 300 or 600 mg twice daily, or 600 or 800 mg once daily. After week 4, study participants continued PEG-IFN/RBV for an additional 44 weeks. To search for resistance variants, Barnard et al. [85] amplified the NS3 region of HCV from RNA purified from patient plasma and performed clonal sequencing on the resulting NS3 amplicons at multiple points during follow-up.
Four patients randomized to receive MK-7009 experienced virological failure by day 42 of the study. Longitudinal resistance analysis revealed that resistance patterns in these patients varied by HCV genotype, with R155K dominating the rebound population in patients infected with subtype 1a, while substitutions at D168 were present in the patient infected with genotype 1b virus. R155K persisted for months after withdrawal of MK-7009. D168T, selected in the patient infected with genotype 1b, also persisted after MK-7009 withdrawal but was largely replaced by wild-type virus by day 168 of the study.
In total, three of five patients experienced virological failure between days 80 and 168, during the 44 weeks PEG-IFN/RBV treatment. One of these patients was infected with genotype 1a virus, and the other two were infected with genotype 1b. In the patient infected with genotype 1a virus, R155K was identified as the dominant variant during virological rebound. However, the patients infected with genotype 1b virus primarily had wild-type virus upon rebound following MK-7009 withdrawal. Resistance variants were observed at a low level (1 of 40 clones) in these two patients infected with genotype 1b virus. However, the investigators could not discern at this point whether these were actual resistance variants, or whether they were an artifact of RT-PCR amplification.
Barnard et al. [85] proposed that R155K is rarely selected upon MK-7009 failure in patients with HCV genotype 1b because it requires two nucleotide changes in that genotype versus one in genotype 1a. D168 variants probably revert to wild-type more readily than R155K because the selected D168 variants are less fit than R155K.
Lenz et al. [86] used population sequencing and 454 deep sequencing to analyse baseline and on-treatment resistance mutations in two trials of TMC435, an HCV NS3/4A PI. In the first trial, TMC435-C101, six IFN-experienced HCV genotype 1 patients received TMC435 monotherapy at a dose of 200 mg once daily for 5 days. Approximately 1.5 years later, five of these six patients were treated in OPERA-1 with the same dose of TMC435 plus PEG-IFN/RBV for 28 days. All four patients who completed 28 days of treatment in OPERA-1 reached an HCV RNA level <25 IU/ml.
Population sequencing detected the Q80K and D168D/E NS3 mutations in two patients before treatment in TMC435-C101. During this trial, population sequencing showed the emergence of mutations at NS3 positions 80, 155 or 168 in all six patients. Population sequencing did not detect those mutations at the start of OPERA-1, but it did detect emergence of new mutations in two patients during the trial, R155K in one person and Q80R, D168E and F169L in the other.
Deep sequencing did not reveal additional baseline mutations before TMC-C101, but this technology did disclose single mutations at a population frequency <2% in three patients at baseline in OPERA-1, Q80L, R156G and R155K. Two patients in OPERA-1 had lower initial decreases in HCV RNA in that trial than in TMC-C101, one patient with R155K at <2% frequency in OPERA-1 and another patient with no detectable mutations when entering OPERA-1. During treatment in OPERA-1, Q80K/R and D168E emerged as major variants and may have blunted the initial decline in HCV RNA. Lenz et al. [86] noted that an ongoing Phase IIb trial will provide additional data on resistance to TMC435.
Wyles et al. [87] assessed resistance selection induced by increasing concentrations of 3-methoxy-2-(phosphonomethoxypropyl)adenine (MPMPA) in HCV genotype 1b replicon cells. MPMPA is an acyclic nucleoside phosphonate that inhibits HCV in vitro. Sequencing disclosed evolution of three unique mutations, Q49L, K50N and Q58L. All of these mutations are within the highly conserved nucleotide triphosphate tunnel of HCV NS5B, or in close proximity to that tunnel.
When introduced into wild-type genotype 2a replicons, K50N and Q49L induced a modest increase in EC 50 (1.7-fold and 1.5-fold, respectively). Wyles et al. [87] could not assess the EC 50 fold change for Q58L because fitness of this variant was so poor they could not generate a dose-response curve. K50N enhanced replicative fitness of the replicons, a result suggesting that it functions as a compensatory mutation. A previously described mutation, S282T, increased the EC 50 of MPMPA 2.5-fold, while increasing the EC 50 of 2-C′-methyl nucleosides 2.4-fold, findings suggesting the possibility of cross-resistance. K50N had no effect on the EC 50 of 2-C′-methyl nucleosides.
In any trial of anti-HCV agents, it is important to understand that failure on monotherapy differs completely from failure when these drugs are combined with PEG-IFN and RBV. In the former case, failure is the direct consequence of resistance, following an HIVlike model. In the latter, the role of IFN-RBV inhibition is crucial and its insufficiency explains why selected variants have been able to evolve and why the infection was not cured.
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